Know Cancer

or
forgot password

The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate


N/A
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate


Inclusion Criteria:



- histological proven adenocarcinoma of the prostate

- T1-T4 tumors

- Radiotherapy as primary therapy +/- androgen deprivation

- Presence of an intraprostatic lesion (IPL) on MRI/MRS

- Presence of an intraprostatic lesion (IPL) on ultrasound

- WHO 0-2

Exclusion Criteria:

- Other primary tumor, except non-melanoma skin cancer

- No written informed consent

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Outcome Measure:

Acute toxicity after implantation of the fiducial gold markers

Outcome Time Frame:

1 week after implantation

Safety Issue:

Yes

Principal Investigator

Gert De Meerleer, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital, Ghent

Authority:

Belgium: Institutional Review Board

Study ID:

2008/109

NCT ID:

NCT00841685

Start Date:

December 2008

Completion Date:

May 2013

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location